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http://dx.doi.org/10.1016/j.jebdp.2014.04.017The Multi-Center Randomized Controlled
Trial (RCT) Published by the Journal of the
American Medical Association (JAMA) on the
Effect of Periodontal Therapy on Glycated
Hemoglobin (HbA1c) Has Fundamental
ProblemsSUMMARY
Subject
Participants had type 2 diabetes, were on stable medication regimens, had
HbA1c levels between 7% and <9%, retained at least 16 natural teeth, and
had untreated chronic periodontitis. A total of 514 participants were
enrolled between November 2009 and March 2012 from diabetes and
dental clinics and communities affiliated with five participating academic
medical centers. They were randomized with half (n = 257) allocated to a
treatment group and the other half (n = 257) to a control group.
Key Exposure/Study Factor
The exposure was non-surgical periodontal treatment comprising scaling
and root planing, oral hygiene instruction, and oral rinsing with chlorhex-
idine provided to the treatment group at baseline. Supportive periodontal
therapy was also provided at 3 and 6 months. The control group received
no treatment for the 6-month duration of the study.
Main Outcome Measure
The primary outcome measure was ‘‘the difference in change in HbA1c
level from baseline between the two groups at 6 months.’’ Secondary out-
comes included changes in periodontal probing depth (PPD), clinical
attachment loss, bleeding on probing (BOP), gingival index, fasting
glucose level, and Homeostasis Model Assessment (HOMA2) score.
Main Results
The authors report that enrollment into their Diabetes and Periodontal
Therapy Trial (DPTT) was terminated early due to futility. At 6 months,
mean HbA1c levels in the periodontal therapy group increased
0.17 (61.0)%, compared with 0.11 (61.0)% in the control group, with
no significant difference between groups based on a linear regression
model adjusting for clinical site (mean difference, 0.05% [95% CI:
0.23% to 0.12%]; p = 0.55). Periodontal measures improved in the treat-
ment group compared with the control group at 6 months, with
adjusted between-group differences of 0.28 mm (95% CI: 0.18–0.37)
for PPD; 0.25 mm (95% CI: 0.14–0.36) for clinical attachment loss;
13.1% (95% CI: 8.1%–18.1%) for BOP; and 0.27 (95% CI: 0.17–0.37) for
gingival index (p < 0.001 for all).
Conclusions
The authors conclude: ‘‘Nonsurgical periodontal therapy did not improve glyce-
mic control in patients with type 2 diabetes and moderate to advanced chronic
TABLE 1. Effect of non-surgical periodontal treatment on glycemic control in people with type 2 diabetes:
meta-analyses published as of July 19, 2014.
Meta-analysis # studies # RCTs Pooled # subjects HbA1c change 95% CI p-value
Janket et al (2005)2 5 1 268 0.66%a 2.2; 0.9 ns
Darre et al (2008)3 9 9 485 0.46%c 0.82; 0.11 0.01
Teeuw et al (2010)4 5 3b 180 0.40%c 0.77; 0.04 0.03
Simpson et al (2010)5
Cochrane Review
3 3 244 0.40% 0.78; 0.01 0.04
Sgolastra et al (2013)6 5 5 315 0.65% 0.88; 0.43 <0.05
Engebretson and Kocher
(2013)7
9 9 775 0.36% 0.54; 0.19 <0.0001
Liew et al (2013)8 6 6 422 0.41% 0.73; 0.09 0.013
CI: confidence interval; HbA1c: glycated hemoglobin; ns: non-significant; RCT: randomized controlled trial.
aWeighted.
bRemaining two non-RCT studies are clinical controlled trials.
cStandardized mean difference.
JOURNAL OF EVIDENCE-BASED DENTAL PRACTICEperiodontitis. These findings do not support the use of nonsur-
gical periodontal treatment in patients with diabetes for the pur-
pose of lowering levels of HbA1c.’’COMMENTARYANDANALYSIS
When developing clinical recommendations and guide-
lines, it is important to consider the highest levels of evi-
dence, which are typically derived from high-quality
systematic reviews of high-quality RCTs that are suffi-
ciently powered and well conducted to provide definitive
evidence. However, individual large multi-center trials are
often perceived by the busy reader to independently
deliver definitive answers to the research question posed.
Hence, the potential impact of the RCT discussed in
this review1 is significant because it will be considered to
provide a higher level of evidence than previous system-
atic reviews of prior smaller studies. The majority of avail-
able studies have reported improvements in glycemic
control (measured as HbA1c) in people with type 2 dia-
betes after non-surgical periodontal therapy. HbA1c mea-
sures long-term blood sugar levels over the lifespan of the
red blood cell, weighted to the last 2 to 3 months. All
seven systematic reviews and meta-analyses published
conclude that such therapy does lead to improvements
in glycemic control. They calculated similar magnitudes
of HbA1c improvement, ranging from 0.36 to 0.65
percentage points (Table 1). This reported impact is
similar to that expected from adding a second oral anti-
diabetes medication tometformin and is therefore of clin-
ical significance in the management of diabetes.
TheUSmulti-centerRCTunder review1,9was anticipated
to be a ‘‘definitive’’ study, unlike its smaller predecessors.
Given the increasing global epidemic of type 2 diabetes
and the need for novel approaches to manage and/or
prevent diabetes and its complications, this multi-center
study conducted in partnership with the funding agency,128the US National Institute of Dental and Craniofacial
Research (NIDCR), is very important because its findings
are likely to influence the current scientific knowledge
base, as well as evidence-based policy-making and clinical
practice in many countries.
The basic goal underlying these intervention studies in
persons with type 2 diabetes is to reduce the local micro-
bial burden to a level sufficient to lead to clinically mean-
ingful improvements in periodontal health. If successful,
the systemic exposure and subsequent inflammatory
burden would be reduced, which would in turn decrease
long-term blood glucose levels, measured as HbA1c. How-
ever, clinically meaningful improvement in periodontal
health that is consistent with the standard of care re-
ported in the world literature is an essential pre-requisite
for a valid outcome. Otherwise, no effect on HbA1c could
reasonably be expected.Concern 1: No Significant Effect of Periodontal
Treatment Would Be Expected Because
Baseline HbA1c Levels Were Already Close to
the Goal for Good Glycemic Control
Hyperglycemia defines diabetes, and its control is funda-
mental to diabetes care.10 The goal for type 2 diabetesman-
agement is to attain and maintain an HbA1c level of less
than 7.0%, but lower (less than 6.5%) or higher (less
than8%) levels are acceptable for specific patient groups.10
The HbA1c value of 7.0% was selected as the lower limit
for enrollment in the study, corresponding to average
plasma glucose levels of 154 mg/dL (8.6 mmol/L). The
upper limit was set at less than 9.0% (212 mg/dL
or 11.8 mmol/L). Nevertheless, 3.5% (9) of the test
participants had HbA1c levels of 9% or greater and 4.7%
(12 subjects) had HbA1c less than 7%, both in violation
of the protocol’s eligibility criteria. The baseline mean
HbA1c level was 7.84% in the treatment group (calculatedSeptember 2014
TABLE 2. Improvement in periodontal measures following non-surgical periodontal treatment: the reviewed RCT
(n = 240; eTable 2a)1 versus literature-based expectations.
Periodontal parameter Baseline1
After
treatment1
Reported
decrease Expected decrease (non-diabetes)
Engebretson
(2013)1 Cobb (1996)12 & (2002)13
Van der
Weijden and
Timmerman
(2002)14
Periodontal probing depth
(PPD) [mean (mm)]
3.3 mm 2.9 mm 0.4 mm
 1.29 mm (PPD 4–6 mm)12
 1.50 mm (PPD = 6 mm)13
 2.16 mm (PPD $ 7 mm)12
 1.18 mm
 1.23 mm
(mild
periodontitis)
 2.26 mm
(severe
periodontitis)
Bleeding on probing
(BOP) [proportion (%)]
60.6% 41.6% 19.0% 45% (PPD 4.0–6.5 mm)13 n/a
Gingival index (GI) 1.4 1.0 0.4 1.013 n/a
n/a: not available.
aBaseline figures differ slightly from Table 1 in the body of the report, which uses n = 257.1
JOURNAL OF EVIDENCE-BASED DENTAL PRACTICEfrom eTable 1) and 7.77% among controls (eTable 1). At
baseline, 60.3% of the test group and 63.8% of the control
group already had HbA1c levels below 8.0%, leaving less
than 40% with HbA1c levels at 8.0% or greater. The poten-
tial for any intervention to improve glycemic control
depends upon the baseline HbA1c level: the higher the
level, the greater the potential for improvement, and the
lower theHbA1c level, themore unlikely a further decrease
becomes. Therefore the HbA1c interval selected for inclu-
sion in this study renders additional benefit from any
adjunctive therapy less likely. With a mean baseline value
of 7.8% and an upper limit for eligibility of less than 9%,
the study subjects were already close to their target for
glycemic control at enrollment.Concern 2: No Conclusion Can Be Drawn
Regarding Any Effect on Glycemic Control
Because Periodontal Treatment Failed to Reach
the Accepted Standard of Care
The reviewed study suffers from a second significant defi-
ciency, namely the poor outcomes reported for the admin-
istered periodontal therapy. The clinical improvements in
periodontal health are far below the expected standard of
care and effectively negate the appropriateness of any
conclusions based on this intervention. Fundamental
to the appropriate interpretation of results from any
periodontal intervention study is that the reductions in
PPD, percent of sites with BOP (%BOP), plaque scores,
and gains in clinical attachment are consistent with the
world literature. When outcomes are below the expectedVolume 14, Number 3standard of care, then the likelihood of incorrect conclu-
sions being drawn is high.11
It is widely recognized that quoting statistically signifi-
cant improvements in clinical outcomes that are based
on the means or medians of hundreds of measures per
patient is inappropriate unless the changes reported
are of clinical significance and, most importantly, consis-
tent with the literature. In Table 2, we have summarized
the outcomes attained after non-surgical periodontal
treatment in this study and compared them to the ex-
pected results in subjects without diabetes from system-
atic reviews. Table 3 displays the periodontal health
status at baseline and at the end of the study. The peri-
odontal treatment in this RCT resulted in poor levels
of clinical improvement and left considerable inflamma-
tion (BOP) and very high dental plaque (infection)
levels, which are highly likely to have precluded any
reduction of HbA1c in the test group and most likely
explain the reported (but not statistically significant) in-
crease in % HbA1c.
It is unfortunate that these essential results are
displayed exclusively in the online supplementary over-
view (eTable 2) and that the authors did not benchmark
their results against the accepted literature.12–14 A key
question that should have been discussed is, ‘‘Why did
the periodontal status of the individuals in the treatment
arm not improve sufficiently and in a manner consis-
tent with the periodontal outcomes in prior studies?’’
Because of the poor clinical improvement in periodontal
conditions, the biological question of whether reducing
periodontal infection/inflammation in a clinically signi-129
TABLE 3. Periodontal health status in the treatment
group (n = 240) at the beginning and at the end of the
study (eTable 2a).1
Periodontal parameter Baseline
End of
study
Periodontal probing depth (PPD)
PPD $4 mm
[mean # sites/person] 50.9 30.6
PPD $5 mm
[mean # sites/person] 28.8 15.7
PPD $4 mm
[proportion sites (%)] 33.7% 20.1%
PPD $5 mm
[proportion sites (%)] 19.0% 10.2%
Clinical attachment loss (CAL)
CAL $4 mm
[mean # sites/person] 59.7 44.0
CAL $5 mm
[mean # sites/person] 35.7 23.6
CAL $4 mm
[proportion sites (%)] 40.1% 29.8%
CAL $5 mm
[proportion sites (%)] 6.6% 4.3%
Bleeding on probing (BOP)
[proportion sites (%)] 60.6% 41.6%
Plaque score
[% sites/person] 86.7% 72.1%
Study eligibility criterion: Moderate to advanced chronic periodontitis,
defined as clinical attachment loss and probing depth of at least
5 mm in 2 or more quadrants.
aBaseline figures differ slightly from Table 1 in the body of the
report1 which uses n = 257.
JOURNAL OF EVIDENCE-BASED DENTAL PRACTICEficant manner results in improved glycemic control
cannot be answered by the results of this study.
The manner in which the authors portray the effect
of the periodontal treatment implies that the treatment
was successful, when in fact, it was not. The authors
claimed: ‘‘Using linear regression models, all periodontal clin-
ical parameters improved significantly at 3 months and were sus-
tained at 6 months in the treatment group but not in the control
group.’’ This statement directly leads the reader to
believe that the periodontal treatment was successful.
However, statistically significant improvements in peri-
odontal outcome parameters are meaningless unless
they have clinical relevance and are consistent with the
standard of care and attainable results reported in the
literature. These results are neither. At the end of the
study, each person still had on average 30.6 sites
(20.1%) with PPD 4 mm or greater, and half of those
(15.7 sites or 10.2%) were 5 mm or deeper; 41.6% of all
sites bled on probing; and 72.1% had plaque (Table 3).
Based on their periodontal status, it seems that a consid-
erable proportion of the participants still had a level of130periodontitis at the completion of the study that would
render themeligible for enrollment into the study for peri-
odontal therapy, based on their current level of periodon-
titis and the study’s own inclusion criteria. The authors
noted: ‘‘improvements in plaque and bleeding scores were only
modest and indicate that changing oral hygiene habits remains
a challenge.’’ However, previous intervention studies did
manage to overcome this challenge and greatly improve
periodontal health. Why could this large multi-center
study not achieve sufficient plaque control consistent
with the literature? The notion suggested by the authors
that ‘‘it is possible that periodontal inflammation and infection
do not influence glycemic control. Indeed, the results of this trial
indicate that glycemic control worsened, although not signifi-
cantly, 6 months after study therapy’’ assumes that periodontal
treatment has been clinically effective. Because it was not,
this statement is not supported by the study results.Concern 3: Pronounced Obesity Would Mask
Any Decrease in Inflammatory Response
Caused by Successful Periodontal Treatment
A third significant problem is that the chronic, low-grade
inflammatory state elicited by the prominent obesity in
the treatment group (meanBMI34.7(67.5) kg/m2)would
have masked any anti-inflammatory effect of successful
periodontal treatment. It is the decrease in inflammation
due to periodontal infection that leads to the decrease in
blood glucose levels, and thus we would not expect to be
able to measure any significant decrease in glycated
hemoglobin levels, even after successful periodontal treat-
ment in such obese subjects. TheHiroshima Study demon-
strated that HbA1c levels improve by resolution of the
periodontal infection-related systemic inflammation, but
only in subjects with initially elevated levels of the acute-
phase inflammatory marker C-reactive protein, measured
with high sensitivity (hsCRP).15 In fact, the initial hsCRP
level is a significantly important independent variable
influencingHbA1c reduction rates, and the greatest reduc-
tion in HbA1c level is experienced by the group with the
highest hsCRP reduction following periodontal treat-
ment.15 Importantly, the subjects in the Hiroshima study
were non-obese but had type 2 diabetes. An earlier US
study called Atherosclerosis Risk in Communities (ARIC)
already reported that, when the BMI of the subjects was
in the 20s range, there was a predicted 2-fold difference
in hsCRP between severe and no/mild periodontitis
groups, but the difference decreased with increasing BMI
and became negligible when BMIs reached 35 kg/m2.16
Furthermore, the Periodontitis and Vascular Events
(PAVE) multi-centered trial demonstrated that systemic
inflammation persisted among obese individuals following
scaling and root planing.17 In the current study, although
the effect of periodontal therapy on the reduction in the
systemic inflammatory burden was not reported, it is
possible that most of the subjects were resistant to theSeptember 2014
JOURNAL OF EVIDENCE-BASED DENTAL PRACTICEelimination of periodontal disease-related systemic inflam-
mation due to the overwhelming influence of their obesity-
related systemic inflammatory load.Conclusion
Overall, this study actually raises more questions than
it answers, which is an important outcome. Regrettably,
it is not the definitive study for determining the effects
of successful periodontal therapy on glycemic control in
people with diabetes that it was anticipated to be.
There is no logical basis for expecting periodontal
treatment that is not successful in controlling the peri-
odontal infection and reducing inflammation to clinically
acceptable levels to have any positive impact on glycated
hemoglobin levels, in particular where obesity levels are
high and glycemic control is close to target at enrollment.
Consequently, the results of this large RCT are inconclu-
sive and the results of this investigation do not permit
meaningful statements to be made regarding whether
or not successful non-surgical periodontal treatment con-
tributes to glycemic control by decreasing HbA1c levels
in people with type 2 diabetes. Unfortunately, this study
failed to achieve periodontal treatment outcomes compa-
rable to those obtained by several existing studies among
people with diabetes in several countries, as well as by
studies enrolling persons without known diabetes.
We call on the periodontal community to urgently
analyze why large multi-center RCTs appear incapable
of effectively treating periodontitis to accepted standards
of care. We also wonder why such costly studies do not
specify in their protocols that periodontal treatment
should be performed to defined clinical endpoints, as
suggested in 2008 by Armitage18 and in 2010 by Offen-
bacher and Beck.19 Such adaptive treatment protocols
would eliminate incomplete or inadequate therapeutic
outcomes and their potential to mislead readers into
believing that any treatment provided as ‘‘per protocol’’
would automatically lead to clinically significant improve-
ments in periodontal health, which subsequently would
affect the outcome studied.Consequences
We are very concerned that, despite these inconclusive re-
sults, the outcomes of this RCT are quoted as ‘‘definitive.’’
Despite the lack of clinically significant improvements in
periodontal health, and because the authors claim there
were significant improvements –without using the qualifier
‘‘statistically significant only’’ – the study is quoted by the
press as demonstrating (‘‘proving’’) that there is no effect
of periodontal treatment on glycated hemoglobin. Addi-
tionally, this study did not address the degree of obesity
of test subjects at all, and the title of the study may mislead
thepublic intobelieving that the results are applicable to all
cases of type 2 diabetes. This is an unsafe and incorrect
conclusion and dangerously misleading to the profession,Volume 14, Number 3the public, and other stakeholders, such as policy makers,
health plan managers, and insurance companies.
Given the inconclusive nature of these data, we recom-
mend that the existing body of evidence in which meta-
analyses consistently conclude that successful periodontal
therapy appears to improve glycemic control, should
instruct us until results from future studies are reported.
We urge all interested parties to refrain from using
these study results as a basis for future scientific texts,
new research projects, guidelines, policies, and advice
regarding the incorporation of necessary periodontal
treatment in diabetes management.REFERENCES
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